At Janssen, we believe transparency helps to advance science and medicine; it’s in the best interests of both the people who use our pharmaceutical products and providers who prescribe them.
The people and healthcare professionals who rely on our products place their trust in the reliability of our clinical research, the rigor of our scientific publications, the independence of medical education we fund and the integrity of our professional relationships.
Our approach to product development and peer-to-peer education is focused on improving the health of people and driving improved clinical outcomes through transparent, compliant activities. Healthcare professionals with real-world clinical experience in specific therapeutic areas are uniquely qualified to provide education and insights into new advancements regarding our products.
Science sometimes advances quickly, and peer-to-peer education can address potential treatment gaps as it allows providers to objectively discuss important medical information with expert colleagues regarding the appropriate use of our products. We believe innovation is enhanced through partnership with medical professionals, institutions and non-profit organizations to further patient care, advance medical progress and enhance the well-being of the communities in which we live and work.
For more information regarding the transparency of the financial relationships between Janssen, physicians and teaching hospitals, please visit your local Janssen website. The full list of Janssen websites is located here.
We hold ourselves accountable to the highest standards to ensure our relationships with Janssen partners are conducted appropriately. We regularly review and amend our practices according to our own ethical standards as well as the standards required of us wherever we operate.
Ultimately, our goal is to foster an environment focused on improving health. We remain committed to addressing unmet needs through investments in research and development, compliant peer-to-peer education and community support.
As a global company broadly based in healthcare, we seek to make meaningful impacts on society while minimizing our impact on the planet. We report our progress on our Citizenship & Sustainability goals annually and have done so for more than 15 years.
Across the enterprise, our processes require that we continue to examine our key citizenship and sustainability performance metrics to see where expansion of data collection efforts may be required. Tracking for several new metrics was added in 2012, including key labor metrics, as well as additional exploration of water availability and biodiversity concerns in the regions where our facilities are located.
For the last several years, we have been following a strategic plan to increase the amount of information provided in our Citizenship & Sustainability Annual Report and on our website, including metrics on our supply chain, human rights, labor practices and other social and environmental indicators. We included numerous new metrics associated with the Global Reporting Initiative (GRI), including LA1, LA13, HR4, PR6, EN11, EN12, among others, which allows our business leaders to target improvement efforts in key areas.
We understand that sharing information about patents can be helpful for a variety of stakeholders. If you would like information about the current status of patents for our medicines, please direct your inquiry to Cori Vail.